Our Pipeline

Biosyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies

First-in-class CAR-T and TCR-T technology against EBV-related cancers

Killing tumor cells by targeting the virus

Reduction of the on-target off-tumor effect, thereby reducing the damage to normal cells and tissues

Largest patented EBV TCR library in the world

Our library of EBV-specific TCR covers over 80% of the patient population with a broad range of HLA types, particularly those predominant in Asia where EBV-related cancers are prevalent.

State-of-the-art GMP production facility

A comprehensive facility for the manufacturing of our proprietary product for clinical use in compliance with Good-Manufacturing-Practice (GMP) guidelines.